Trial reportActa paediatrica (Oslo, Norway : 1992)2025
Bumetanide Treatment in 15 Children With Autism: A Randomised Waitlist-Control Study.
Trial report in Acta paediatrica (Oslo, Norway : 1992), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
aimBumetanide, a diuretic, influences neuronal chloride homeostasis and potentially restores GABAergic inhibition and neuronal signalling balance. This mechanism may contribute to improvements in autism-related symptoms. The present study builds on the preclinical research and on previous clinical research on bumetanide treatment for children with autism.
methodsFifteen children (10 boys, 5 girls), aged 4-12 years with a clinically confirmed autism diagnosis, with and without intellectual disability and with and without ADHD were enrolled in this 9-month randomised waitlist-control study. Participants were randomly assigned to either begin bumetanide treatment immediately or wait 3 months before starting. Parents completed rating scales assessing symptoms, behaviours and functioning at baseline and after 3, 6 and 9 months.
resultsTwo children had to be excluded in the first treatment period with bumetanide due to emerging behavioural problems. Of the remaining 13, 4 discontinued after the 4-6 months period with bumetanide, and 9 completed the full 9-month study. According to parent reports, 4 of these 9 children experienced significant clinical improvements, leading parents to opt for continued bumetanide treatment for their child after study completion.
conclusionThis small, waitlist-control study provides further support that bumetanide may have beneficial effects for some children with autism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.